X0609 4 2026-06-15 0000907654 Oruka Therapeutics, Inc. ORKA 0001756991 Goncalves Joana false C/O ORUKA THERAPEUTICS, INC. 855 OAK GROVE AVE., SUITE 100 MENLO PARK CA 94025 0 1 0 0 Chief Medical Officer 1 Common Stock 2026-06-15 4 M 0 3500 6.84 A 37165 D Common Stock 2026-06-15 4 M 0 3500 7.80 A 40665 D Common Stock 2026-06-15 4 S 0 1636 68.3839 D 39029 D Common Stock 2026-06-15 4 S 0 5064 69.4209 D 33965 D Common Stock 2026-06-15 4 S 0 300 70.6233 D 33665 D Common Stock 2026-06-15 4 S 0 947 69.69 D 32718 D Employee Stock Option (right to buy) 6.84 2026-06-15 4 M 0 3500 0 D 2034-05-06 Common Stock 3500 204063 D Employee Warrant (right to buy) 7.80 2026-06-15 4 M 0 3500 0 D 2034-07-14 Common Stock 3500 175492 D Includes 288 shares acquired under the Oruka Therapeutics, Inc. stock purchase plan on June 8, 2026. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.97 to $68.96, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.98 to $69.83, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.79, inclusive. These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. /s/ Paul Quinlan, as attorney-in-fact for Joana Goncalves 2026-06-15